Articles tagged with Cancer Patients
A new study found that one-third of popular cancer treatment articles on social media contain misinformation, which can negatively impact patient outcomes. The vast majority of this misinformation garners more attention and engagement than evidence-based information.
A study published by The BMJ found that remote 24-hour monitoring for cancer patients receiving chemotherapy significantly reduces symptom burden, anxiety, and work limitations. Patients who used the system experienced improved quality of life and reduced supportive care needs.
Researchers developed patient-specific tumor organoids to test immunotherapy treatments for appendiceal cancer. The study found that various types of immunotherapies can achieve personalized results, identifying beneficial treatments while sparing patients from harmful side effects.
A Ludwig Cancer Research study has found that transient chromosomal instability events can lead to the formation of tumors in mice. The researchers induced random chromosome instability in mice for one week and found that this was enough to trigger harmful chromosomal patterns that spur tumorigenesis.
Researchers at UC Davis Comprehensive Cancer Center are investigating whether turmeric can successfully reduce joint pain in breast cancer patients and improve their quality of life. The study aims to provide important data on the safety and effectiveness of using turmeric with oral anti-estrogen therapy.
Researchers investigated CEA as a blood-based biomarker for anal cancer. Although CEA levels correlated with disease progression, they were not associated with survival outcomes or clinically relevant in managing the disease. Novel approaches with serum biomarkers are necessary for this rare and increasing diagnosed malignancy.
Researchers found a 40% objective response rate for patients with advanced malignant peritoneal mesothelioma treated with atezolizumab and bevacizumab. The treatment was well-tolerated, with improved progression-free and overall survival rates compared to standard chemotherapy.
A new study found that obese patients with advanced prostate cancer survive longer than their overweight and normal-weight counterparts. Obesity was associated with a 10% higher survival rate over 36 months. The 'obesity paradox' suggests that high body mass index may be protective in certain cases.
Researchers will analyze and map environmental, social, and economic factors that impact cancer diagnosis in a regional patient data set. The study aims to identify correlations between potential causes and common types of cancer in the region.
A recent study published in the American Journal of Roentgenology found that reduced-dose CT scans can detect greater than 90% of lung nodules in children and young adults with cancer. This could lead to a reduction in patient dose while maintaining high diagnostic accuracy.
A new study predicts patient responses to immunotherapy using tumor fragments in the lab, offering hope for personalized cancer treatment. The researchers identified specific immune cell markers that can predict treatment response and resistance.
A pilot study found that patients with high cotinine levels were four times more likely to have their cancer return. The researchers aim to develop a simple urine test for cotinine to reduce invasive investigations for bladder cancer patients.
Research found nearly two-thirds of patients with non-muscle-invasive bladder cancer had multiple co-existing chronic conditions, leading to a mean treatment burden of 8.9 days. Rural patients consistently had higher treatment burden than urban counterparts.
Researchers have developed a novel method for generating metabolic profiles of individual cells, enabling the analysis of over 100 metabolites and lipids from thousands of cells per hour. The method, called SpaceM, uses a combination of fluorescence microscopy and mass spectrometry to analyze single-cell metabolism.
Researchers discover pharmacological activation of p53 triggers viral mimicry response, abolishing tumor immune evasion and promoting anti-tumor immunity. The findings have potential for developing new combination therapies that can increase cancer patient access to immunotherapy.
A recent study found that nearly all patients with cancer developed good immune responses to COVID-19 mRNA vaccines, with 94% developing antibodies. However, a small subset of high-risk patients showed no response, raising concerns about future vaccination strategies.
The RESILIENCE project seeks to prevent anthracycline-induced cardiotoxicity in cancer patients through remote ischaemic preconditioning, with over 600 patients enrolled in a randomised clinical trial. Cardiac function will be evaluated using state-of-the-art cardiac magnetic resonance imaging.
A new assessment tool has been found to predict ovarian damage in girls with cancer, helping doctors determine which patients should undergo fertility preservation. The Edinburgh selection criteria identify high-risk patients who are more likely to develop premature ovarian failure.
Researchers have developed a chemical compound that produces a powerful oxygen reaction when exposed to light, selectively killing cancer cells while leaving surrounding tissue intact. The photodrug is currently in clinical trials for patients with recurring bladder cancer resistant to traditional therapies.
Boston University School of Medicine has received a grant of $2.7M from the American Heart Association to study disparities in cardio-oncology and their impact on cardiovascular disease among diverse populations. The research aims to better understand the causes, consequences, treatment, and prevention of CVD among cancer patients.
A large cohort study found that patients with heart failure are more likely to develop cancer compared to those without. The incidence of cancer was significantly higher among heart failure patients, particularly for certain types of cancer such as lip, oral cavity, and pharynx cancers.
A pilot study found children with acute lymphocytic leukemia were four times more likely to live near oil and gas sites than other cancer patients. The new study aims to determine if there's a potential link between benzene emissions from oil and gas production and childhood ALL.
A study evaluated a panel of 142 mutation-signature–associated metrics for predicting cancer progression in patients. The P142 panel successfully predicted cancer progression status in some, but not all, analyzed cancer types.
An international study on rare childhood cancer, rhabdomyosarcoma, found that mutations in genes TP53, MYOD1, and CDKN2A are associated with a more aggressive form of the disease. The study provides genetic clues for developing targeted therapies.
Researchers developed a new dietary fiber formulation that modulates the gut microbiome, improving potency of immunotherapies against cancer. The inulin gel doubled the rate of tumor eradication in rodents with colon carcinoma and melanoma, expanding beneficial microbes in the gastrointestinal tract.
Researchers identified FTO as a key regulator of cancer metastasis and found that lowering its levels enhances WNT signaling, making tumors more sensitive to WNT inhibitors. This discovery offers encouraging prospects for treating aggressive cancers.
The 2021 ESMO World Congress on Gastrointestinal Cancer presented new concepts in clinical trials, advances in surgery and transplant, and novel immuno-oncology mechanisms. Researchers shared findings on the effects of drug interactions in GI oncology and strategies to improve outcomes for patients with metastatic pancreatic cancer.
Researchers developed a blood test that analyzes circulating tumor DNA to predict treatment response in metastatic HPV-positive throat cancer. The test showed promise in identifying non-responding patients months earlier than standard imaging scans.
Researchers at Memorial Sloan Kettering Cancer Center developed a machine-learning approach that accurately predicts how human breast cancer tumors will evolve. By analyzing genetic makeup of thousands of individual cells, the team created a model that can predict tumor behavior and identify potential relapse sites.
Researchers at USC Norris Comprehensive Cancer Center found that family-based cancer clustering occurs more frequently among Latino, African American, and Asian/Pacific Islander families. The study suggests a higher inherited risk of early-onset cancer in these minority populations compared to non-Latino white families.
A new treatment sequence for esophageal cancer may improve patient outcomes by treating microscopic disease first. The approach adds chemotherapy for two to three months before radiation and surgery, potentially reducing mortality rates.
A recent study found that statin use among patients with heart failure is associated with a 16% lower risk of developing cancer and a 26% reduced risk of dying from cancer over an average of four years. The longer patients remained on statins, the greater the reduction in their cancer risk.
Ovarian cancer is the most lethal gynaecological cancer with an absence of screening programmes, leading to late diagnosis and poor prognosis. Despite targeted therapies, personalized medicine remains a challenge due to inconsistent symptoms and resistance to chemotherapy.
A blood test detecting tiny amounts of circulating cancer DNA may identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery. The study found patients with a particular cancer DNA marker in their blood had a higher likelihood of cancer relapse, suggesting the potential for personalized treatment.
Researchers from the University of Texas Health Science Center at San Antonio developed a new tool to stop hiccups, FISST, which showed nearly 92% success rate in relieving symptoms. Users reported high degrees of effectiveness and ease of use, with most finding it easy to use and very happy with results.
A new classification of metastatic testicular cancer enables more targeted treatment, improving survival rates. The study reveals significant improvements in prognosis for patients with testicular cancer, with increased 5-year survival rates across all groups.
A recent study found a direct molecular link between red meat consumption and colorectal cancer development, revealing genetic mutations indicative of DNA damage. High red meat intake was associated with increased cancer-related mortality and poorer patient survival.
Researchers at Moffitt Cancer Center have developed a non-invasive method to measure PD-L1 biomarker levels in lung cancer patients using PET/CT scan images. This approach uses deep learning to predict checkpoint inhibitor outcomes, which could help determine optimal treatment strategies for patients.
Five researchers, supported by a $12.8 million grant, will investigate computational methods for predicting immunotherapy responses, genetic elements controlling gene expression, and protein assemblies regulating gene expression in cancer.
A study published in the Journal for ImmunoTherapy of Cancer found that immunotherapy outcomes differ based on dosing strategy and patient weight. Overweight patients receiving weight-based dosing lived an average of over 20 months, compared to less than 10 months for lighter patients.
A study found that nearly half of patients with gynecologic cancer experience financial toxicity, which can lead to worsening health outcomes. Younger patients are at a higher risk due to limited financial safety nets and ability to work.
Researchers found that pralsetinib achieved an overall response rate of 70% and complete response rate of 11% in patients with no prior systemic treatment for advanced RET fusion-positive NSCLC. In the thyroid arm, the ORR was 71% in patients with treatment-naïve RET-mutant medullary thyroid cancer.
A large study found that COVID-19 vaccines induce a strong immune response in patients with various types of cancer, with high seroconversion rates among solid tumor patients. However, those receiving treatments for blood cancers had lower but still significant rates, highlighting the importance of vaccination in vulnerable populations.
Research shows that hospitalized individuals with active cancer are more likely to die from COVID-19 than those with a history of cancer or no cancer diagnosis. Patients with blood-related cancers face the greatest risk of death, while recent cancer therapy is not linked to worse outcomes.
A recent study found that fewer than one in three women aged 64 to 66 met the criteria to discontinue cervical cancer screening. The majority of women in this age group may be at risk for cervical cancer due to inadequate screening or preexisting high-risk conditions.
A £8 million project led by the University of Warwick aims to develop new technology combining probes that detect cancer tumours through the skin with high-precision robotic surgery. The Terabotics project has the potential to lead to real-time diagnosis and more comprehensive removal of tumours with reduced need for follow-up surgery.
Researchers at Mayo Clinic Cancer Center found that remote patient monitoring reduced the risk of hospitalization for cancer patients with COVID-19 by 78%. The program used in-home technology to monitor oxygen levels and vital signs, resulting in fewer hospitalizations and ICU admissions.
The Phase II study showed that sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). The drug was found to be safe and tolerable, with manageable toxicities.
Researchers at the University of Turku discovered a novel antibody treatment that reactivates the immune defense system in patients with advanced-stage cancer. The treatment activates killer T cells and lowers the suppressive potential of macrophages, leading to increased inflammation and white blood cell activity.
Researchers found that nivolumab significantly reduced bladder cancer recurrence after surgery in high-risk patients. Disease-free survival was 21 months for nivolumab recipients compared to 10.9 months for placebo recipients.
A national survey of breast cancer patients and oncologists reveals that nearly three-quarters of patients use complementary medicine during treatment, yet doctors often fail to discuss integrative health with patients. Patients report finding hope and improving quality of life through these therapies.
The study found that rivaroxaban is safe for patients with luminal gastrointestinal cancer, while apixaban should be used cautiously due to higher bleeding risk. DOACs can also be used in non-luminal GI cancers like pancreatic and hepatobiliary cancers.
Researchers found that aging decreases T-cell survival and function, while ceramide signaling weakens anti-tumor T-cells. Blocking certain ceramide molecules improves the anti-tumor function of aging T-cells.
A biomarker based on circulating tumour DNA (ctDNA) can predict the likelihood of bowel cancer recurrence after surgery and chemotherapy. The test measures ctDNA levels before and after treatment to provide real-time information on chemotherapy effectiveness.
Researchers at UNIGE create 3D spheroidal tumor models incorporating tumor cells and patient-specific immune cells to test treatment efficacy. This innovative approach enables personalized treatment options, potentially reducing reliance on animal experiments.
A new study published in PLOS ONE demonstrates the potential of machine learning to identify high-risk patients with pancreatic cancer up to 2 years before diagnosis. The algorithm achieved high sensitivity and specificity rates, identifying 41% of patients under 60 as high risk and 72% of those diagnosed as having a detectable risk. T...
Researchers at Huntsman Cancer Institute have identified a specific gene-regulating protein complex to target in the treatment of synovial sarcoma. The study provides new understanding of how the disease develops and spreads, offering potential breakthroughs in diagnosis and therapy.
A phase 3 clinical trial shows that immunotherapy nivolumab after surgery can nearly double the time before relapse for patients with high-risk urothelial cancer. The treatment significantly reduces metastatic recurrence risk, offering hope for thousands of patients worldwide.
The La Jolla Institute for Immunology has launched the Cancer Epitope Database and Analysis Resource (CEDAR), a new global cancer immunology resource, thanks to $4.2 million in National Cancer Institute funding. Researchers can now easily search and contribute data on potential immune system targets on various types of cancer cells.
A study found that cancer patients had lower SARS-CoV-2 antibody levels compared to healthcare workers. Health care workers in Japan had higher SARS-CoV-2 antibody levels, indicating a possible immune response to the virus.